Summary of Results in the year ended 30 June 2017
- Total income (revenue and grant income) decreased 9% to £270,465 (2016: £297,120)
- The operating loss before exceptional costs increased 20% to £489,190 (2016: £408,614)
- The loss for the year attributable to equity shareholders increased 6% to £400,526 (2016: £378,697)
- On 30 June 2017, the surplus of shareholders’ funds was £328,254 (2016: £204,153)
This year, Physiomics focused on extending and initiating new client projects utilizing its Virtual Tumour Clinical technology and in addition invested in an Innovate UK funded feasibility study in the area of personalised medicine that may provide a meaningful second arm to the Company’s business going forwards.
Please click here to read more.